FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W28980388> ?p ?o ?g. }

• W28980388 endingPage "33C" @default.
• W28980388 startingPage "27C" @default.
• W28980388 abstract "This paper summarizes the results of 4 double-blind studies of antihypertensive therapy in which mibefradil was compared with other commonly used calcium antagonists (diltiazem CD, amlodipine, nifedipine SR, and nifedipine GITS) at the recommended dose range. A total of 640 patients were included, with 361 randomized to mibefradil, 98 to diltiazem CD, 119 to amlodipine, 71 to nifedipine SR, and 36 to nifedipine GITS. Trials included an active treatment phase of 6 or 12 weeks in duration. Compared with diltiazem CD or nifedipine SR, mibefradil demonstrated statistically significant greater efficacy. Decreases in sitting diastolic blood pressure (SDBP) after treatment with mibefradil 100 mg once daily were 14.0 +/- 7.8 mm Hg compared with 9.5 +/- 7.5 mm Hg with diltiazem CD 360 mg once daily (p = 0.001), and 12.8 +/- 8.4 mm Hg compared with 8.1 +/- 19.2 mm Hg with nifedipine SR 40 mg twice daily (p = 0.014). Patients on mibefradil also had higher normalization (SDBP reduced to < or = 90 mm Hg) and response (SDBP reduction > or = 10 mm Hg or normalization) rates than did those on diltiazem CD or nifedipine SR. The overall incidence of adverse events was similar among these 3 compounds, but the number of premature withdrawals due to adverse events was greater with both comparators than with mibefradil. Treatment with 100 mg mibefradil or 10 mg amlodipine once daily resulted in statistically significant decreases from baseline in SDBP of 11.5 +/- 8.2 mm Hg and 13.2 +/- 7.9 mm Hg, respectively, which were statistically equivalent. However, patients treated with amlodipine had a considerably greater incidence of leg edema than did those treated with mibefradil (33.6% vs 4.2%, respectively). Similarly, 100 mg mibefradil was equivalent in efficacy to 60 mg nifedipine GITS once daily, but patients on mibefradil experienced fewer vasodilatory related adverse events. In summary, mibefradil demonstrated superior efficacy to diltiazem CD and nifedipine SR and equivalent efficacy to amlodipine and nifedipine GITS in the treatment of hypertension." @default.
• W28980388 created "2016-06-24" @default.
• W28980388 creator A5003871142 @default.
• W28980388 creator A5012168886 @default.
• W28980388 creator A5026827724 @default.
• W28980388 creator A5039593862 @default.
• W28980388 creator A5085654254 @default.
• W28980388 date "1997-08-01" @default.
• W28980388 modified "2023-10-07" @default.
• W28980388 title "Mibefradil in the Treatment of Systemic Hypertension" @default.
• W28980388 cites W1966980453 @default.
• W28980388 cites W1982690791 @default.
• W28980388 cites W1999596364 @default.
• W28980388 cites W2017554908 @default.
• W28980388 cites W2030257202 @default.
• W28980388 cites W2034877370 @default.
• W28980388 cites W2038460733 @default.
• W28980388 cites W2040569221 @default.
• W28980388 cites W2042964099 @default.
• W28980388 cites W2076123097 @default.
• W28980388 cites W2092805838 @default.
• W28980388 cites W2145270758 @default.
• W28980388 cites W2163367728 @default.
• W28980388 cites W2170364275 @default.
• W28980388 doi "https://doi.org/10.1016/s0002-9149(97)00567-5" @default.
• W28980388 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9286851" @default.
• W28980388 hasPublicationYear "1997" @default.
• W28980388 type Work @default.
• W28980388 sameAs 28980388 @default.
• W28980388 citedByCount "15" @default.
• W28980388 countsByYear W289803882014 @default.
• W28980388 crossrefType "journal-article" @default.
• W28980388 hasAuthorship W28980388A5003871142 @default.
• W28980388 hasAuthorship W28980388A5012168886 @default.
• W28980388 hasAuthorship W28980388A5026827724 @default.
• W28980388 hasAuthorship W28980388A5039593862 @default.
• W28980388 hasAuthorship W28980388A5085654254 @default.
• W28980388 hasConcept C126322002 @default.
• W28980388 hasConcept C164705383 @default.
• W28980388 hasConcept C197934379 @default.
• W28980388 hasConcept C2776741139 @default.
• W28980388 hasConcept C2778673320 @default.
• W28980388 hasConcept C2779066535 @default.
• W28980388 hasConcept C2779646130 @default.
• W28980388 hasConcept C519063684 @default.
• W28980388 hasConcept C57900726 @default.
• W28980388 hasConcept C71924100 @default.
• W28980388 hasConcept C84393581 @default.
• W28980388 hasConcept C85520022 @default.
• W28980388 hasConceptScore W28980388C126322002 @default.
• W28980388 hasConceptScore W28980388C164705383 @default.
• W28980388 hasConceptScore W28980388C197934379 @default.
• W28980388 hasConceptScore W28980388C2776741139 @default.
• W28980388 hasConceptScore W28980388C2778673320 @default.
• W28980388 hasConceptScore W28980388C2779066535 @default.
• W28980388 hasConceptScore W28980388C2779646130 @default.
• W28980388 hasConceptScore W28980388C519063684 @default.
• W28980388 hasConceptScore W28980388C57900726 @default.
• W28980388 hasConceptScore W28980388C71924100 @default.
• W28980388 hasConceptScore W28980388C84393581 @default.
• W28980388 hasConceptScore W28980388C85520022 @default.
• W28980388 hasIssue "4" @default.
• W28980388 hasLocation W289803881 @default.
• W28980388 hasLocation W289803882 @default.
• W28980388 hasOpenAccess W28980388 @default.
• W28980388 hasPrimaryLocation W289803881 @default.
• W28980388 hasRelatedWork W1990352572 @default.
• W28980388 hasRelatedWork W2014605795 @default.
• W28980388 hasRelatedWork W2079663656 @default.
• W28980388 hasRelatedWork W2082224281 @default.
• W28980388 hasRelatedWork W2107446775 @default.
• W28980388 hasRelatedWork W2389828681 @default.
• W28980388 hasRelatedWork W2406671530 @default.
• W28980388 hasRelatedWork W2410650146 @default.
• W28980388 hasRelatedWork W3143883744 @default.
• W28980388 hasRelatedWork W1582911544 @default.
• W28980388 hasVolume "80" @default.
• W28980388 isParatext "false" @default.
• W28980388 isRetracted "false" @default.
• W28980388 magId "28980388" @default.
• W28980388 workType "article" @default.